Jagsonpal Pharmaceuticals Limited develops and markets pharmaceutical products, with a focus on branded medicines across selected therapeutic categories. Its established brands and domestic distribution network provide a foundation for growth. Rising healthcare spending and increasing demand for branded formulations support long-term opportunities. Product development and expansion of its therapeutic portfolio can improve competitiveness. Distribution expansion and stronger brand-building can support future growth.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹1,433 cr | ₹294 cr | ₹46 cr | 32.0 | 6.80 | 5.19 | 16.7% | 25.9% | 22.7% | 0.00 | ₹47 cr | 21.0 | 0.46 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 82 | 13 | 2.00 | +25.0% | +8.8% | 16.0% |
| Mar 2026 | 64 | 9 | 1.25 | +27.6% | +9.6% | 13.7% |
| Dec 2025 | 73 | 11 | 1.67 | -64.8% | -1.5% | 15.0% |
| Sep 2025 | 74 | 13 | 1.88 | +9.6% | -0.3% | 16.9% |
| Jun 2025 | 76 | 11 | 1.60 | +106.2% | +23.1% | 14.3% |
| Mar 2025 | 59 | 7 | 0.98 | +87.0% | +34.7% | 11.2% |
| Dec 2024 | 74 | 32 | 4.74 | +700.7% | +56.7% | 43.2% |
| Sep 2024 | 75 | 12 | 1.72 | +51.1% | +29.2% | 15.3% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✓ Pass |
| EPS growth accelerating over 3 quarters | ✗ Fail |
| Sales up 25%+, or sales growth accelerating | ✗ Fail |
| Annual EPS up 25%+ in each of the last 2 years | ✗ Fail |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 161.07 ✓ Within 25% of the 52-week high · high 243.97 ✗ RS percentile 70 or more · RS 59 Trend template - the gate, measured: a modest 21-day edge. | 6/8 | 6 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | ✓ C latest quarter EPS up 25%+ ✗ A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 243.97 ✓ S more volume on up days than down days (50 sessions) · 3.43x ✗ L RS percentile 80 or more · RS 59 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 4/6 | Average |
| Darvas | ✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box. | 10/100 | No box |
| Turtle | ✗ Close above the prior 55-session high · 263.70 ✗ Close above the prior 20-session high · 251.00 ✗ Close below the prior 20-session low · 217.20 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 4.8% — Return on capital (ROCE) · 22.7% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 62/100 | Average |
| Graham | ✗ Price at or below the Graham number · Graham number 80.11 ✗ P/E 15 or less · P/E 32.0 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 5.19 ✓ Current ratio 2 or more · 5.06 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 37/100 | Expensive |
| Piotroski | ✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✗ ROA rising ✓ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✗ Current ratio rising · 5.06 ✗ No new shares issued ✗ Margin rising (net margin) ✗ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 4/9 | Weak |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JAGSNPHARM this stock | -4.7 | -2.4 | +17.4 | -0.9 | +29.6 | +235.6 | 32.0 | 5.19 | 16.7 | 22.7 | — | 0.00 | 21.0 | 1,433 | 294 | 46 | 6.8 | 0.46 |
| BLISSGVS | -8.0 | +29.9 | +147.2 | +312.3 | +606.5 | +476.9 | 48.7 | 5.57 | 11.5 | 16.8 | — | 0.00 | 29.3 | 6,650 | 1,005 | 142 | 12.9 | 1.10 |
| VENUSREM | +0.7 | -5.9 | +55.8 | +252.6 | +518.8 | +242.4 | 18.3 | 3.21 | 16.8 | 21.9 | — | 0.00 | 13.7 | 2,130 | 811 | 116 | 86.9 | 0.88 |
| INDSWFTLAB | -5.7 | +50.4 | +153.3 | +247.2 | +287.1 | +472.2 | 51.6 | 2.21 | 3.2 | 3.9 | — | 0.01 | 33.4 | 3,056 | 665 | 57 | 6.8 | 0.78 |
| MOREPENLAB | +0.5 | +108.6 | +194.2 | +152.6 | +242.7 | +132.7 | 47.5 | 5.34 | 7.9 | 10.1 | — | 0.16 | 40.2 | 6,657 | 1,951 | 140 | 2.6 | 1.46 |
| SHILPAMED | -14.2 | +40.1 | +113.1 | +146.1 | +421.3 | +189.7 | 57.3 | 6.61 | 9.8 | 11.4 | — | 0.25 | — | 17,130 | 1,682 | 297 | 15.3 | 0.87 |
| RUBICON | -15.1 | -1.7 | +60.3 | +140.3 | — | — | 83.8 | 19.08 | 22.4 | — | — | 0.20 | 61.3 | 24,587 | 1,936 | 288 | 17.7 | 0.34 |
| LAURUSLABS | +5.9 | +32.7 | +83.2 | +129.9 | +421.9 | +235.3 | 88.9 | 21.09 | 18.2 | 17.9 | — | 0.45 | 62.0 | 1.12L | 8,839 | 1,252 | 23.3 | 0.74 |
| ZIMLAB | +2.0 | +14.2 | +73.3 | +101.9 | +17.5 | — | 168.5 | 2.50 | 2.1 | 5.5 | — | 0.42 | 21.1 | 740 | 397 | 4 | 0.8 | 0.75 |
| ACUTAAS | -5.4 | -11.0 | +35.0 | +97.5 | — | — | 69.0 | 16.11 | 24.0 | 31.7 | — | 0.02 | 49.9 | 26,636 | 1,462 | 387 | 47.2 | 0.77 |
| IOLCP | -9.8 | +17.8 | +108.9 | +87.8 | +99.0 | +56.2 | 32.0 | 2.99 | 7.9 | 10.7 | — | 0.07 | 20.7 | 5,376 | 2,524 | 168 | 5.7 | 1.13 |